SNDX News and Press, Syndax Pharmaceuticals Inc. From 12/14/23

Syndax Announces Proposed $150 Million Public Offering of Common Stock PR Newswire WALTHAM, Mass. , Dec. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an inn...

2023-12-12 16:54:38 ET More on Incyte Incyte Corporation (INCY) Q3 2023 Earnings Call Transcript Incyte Corporation 2023 Q3 - Results - Earnings Call Presentation Incyte: One Of The Most Undervalued Pharmaceuticals Goldman Sachs cuts Incyte to hold, cites Jak...

Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting PR Newswire – Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis ...

2023-12-11 12:40:05 ET More on Syndax Pharmaceuticals Syndax Pharmaceuticals Inc (SNDX) Q3 2023 Earnings Call Transcript Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023 BofA starts Syndax at buy, cites "first mover advantage" for leukemia drug ...

Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials PR Newswire - Data collectively highlight revumenib's combination potential with current standard of care agents and support adv...

- Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment - Data are featured in the Plenary Scientific Session at the 65 th American Society of Hematology Ann...

Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting PR Newswire WALTHAM, Mass. , Dec. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing a...

Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting PR Newswire WALTHAM, Mass. , Nov. 21, 2023 /PRNewswire/ -- Syndax Pharmaceuticals ...

Syndax Announces Participation at Stifel Healthcare Conference PR Newswire WALTHAM, Mass. , Nov. 7, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Syndax Pharmaceuticals Inc. (SNDX) is expected to report $-0.8 for Q3 2023